Stocks · News reference
Castle Biosciences Q2 Adj. EPS $(0.07) Beats $(0.41) Estimate, Sales $103.546M Beat $86.240M Estimate
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 30, 2026, 8:06 PM
- Checked
- Jul 30, 2026, 8:06 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
BTIG Maintains Buy on Castle Biosciences, Raises Price Target to $44
BTIG analyst Mark Massaro maintains Castle Biosciences (NASDAQ:CSTL) with a Buy and raises the price target from $40 to $44.
Read original at benzingaCastle Biosciences shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY2026 sales guidance above estimates.
Read original at benzingaCastle Biosciences Raises FY2026 Sales Guidance from $345.000M-$355.000M to $365.000M-$375.000M vs $352.291M Est
Read original at benzinga